- Home
- SNTI vs IMNN Comparison
SNTI vs IMNN Comparison
Compare SNTI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- IMNN
- Stock Information
- Founded
- SNTI 2016
- IMNN 1982
- Country
- SNTI United States
- IMNN United States
- Employees
- SNTI N/A
- IMNN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- IMNN Health Care
- Exchange
- SNTI Nasdaq
- IMNN Nasdaq
- Market Cap
- SNTI 85.3M
- IMNN 12.1M
- IPO Year
- SNTI N/A
- IMNN 1985
- Fundamental
- Price
- SNTI $2.21
- IMNN $0.60
- Analyst Decision
- SNTI Strong Buy
- IMNN Buy
- Analyst Count
- SNTI 2
- IMNN 2
- Target Price
- SNTI $8.50
- IMNN $14.00
- AVG Volume (30 Days)
- SNTI 434.6K
- IMNN 1.3M
- Earning Date
- SNTI 08-12-2025
- IMNN 08-13-2025
- Dividend Yield
- SNTI N/A
- IMNN N/A
- EPS Growth
- SNTI N/A
- IMNN N/A
- EPS
- SNTI N/A
- IMNN N/A
- Revenue
- SNTI N/A
- IMNN N/A
- Revenue This Year
- SNTI N/A
- IMNN N/A
- Revenue Next Year
- SNTI $150.00
- IMNN N/A
- P/E Ratio
- SNTI N/A
- IMNN N/A
- Revenue Growth
- SNTI N/A
- IMNN N/A
- 52 Week Low
- SNTI $1.52
- IMNN $0.37
- 52 Week High
- SNTI $16.94
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- SNTI 43.19
- IMNN 35.40
- Support Level
- SNTI $2.10
- IMNN $0.70
- Resistance Level
- SNTI $2.43
- IMNN $0.86
- Average True Range (ATR)
- SNTI 0.18
- IMNN 0.07
- MACD
- SNTI 0.05
- IMNN -0.03
- Stochastic Oscillator
- SNTI 79.25
- IMNN 0.05
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).